Is AbCellera Biologics (ABCL) Undervalued On Strong Earnings And Clinical Data?

AbCellera Biologics (ABCL) has become a focus after reporting quarterly results that exceeded earnings and revenue estimates, along with encouraging Phase 2 and Phase 1 data for key antibody programs that clarify its clinical and funding roadmap.

The latest moves suggest traders are leaning into AbCellera Biologics’ story again, with a 5.22% 1 day share price return and 12.41% 7 day share price return at a US$12.50 price. This builds on a 264.43% year to date share price return and 210.17% 1 year total shareholder return, even though longer term total returns over five years remain negative at 23.73%.

Scan how AbCellera Biologics compares to other fast-moving biotech stories by reviewing the hand-picked 19 high quality undiscovered gems moving on fresh data, liquidity, and clinical catalysts.

AbCellera Biologics has already delivered a very large rebound, yet the business is still loss making and early in its pipeline journey. How much of the potential is already reflected in a US$12.50 share price?

Most Popular Narrative: 27% Undervalued

On the analyst consensus Narrative on Simply Wall St, AbCellera Biologics screens as undervalued, with a fair value of about $17.17 against a last close of $12.50. This puts the current enthusiasm in context for anyone tracking the recent rebound.

The analysts have a consensus price target of $17.17 for AbCellera Biologics based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $30.0, and the most bearish reporting a price target of just $9.0.

See why 61 investors see AbCellera Biologics as 27% undervalued.

Result: Fair Value of $17.17 (UNDERVALUED)

Still, the AbCellera Biologics story can change quickly if late stage data disappoints, or if ongoing operating losses and higher R&D spending weigh more heavily on sentiment.

Find out about the key risks to this AbCellera Biologics narrative.

Next Steps

Mixed feelings after reading about AbCellera Biologics’ rebound and valuation are normal, and this is exactly when your own homework matters most. Move quickly, stress test both the upside and the weak spots, and then ground your view in the 1 key reward and 3 important warning signs.

Looking for more investment ideas beyond AbCellera Biologics?

If AbCellera Biologics has sharpened your appetite for opportunity, do not stop here. Broaden your watchlist now so you are not chasing the next move after it happens.

• Target potential mispricings by scanning a curated mix of quality companies that still trade below internal estimates of worth using the 33 high quality undervalued stocks.
• Prioritize resilience by reviewing a list of solid balance sheet and fundamentals (25 results) that can help you focus on businesses built to handle tougher conditions.
• Anchor your cash flow with income ideas and sift through a hand picked pool of 6 dividend fortresses that combine yield with staying power.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com